Aptose Biosciences Inc. to Post FY2025 Earnings of $0.29 Per Share, Oppenheimer Forecasts (NASDAQ:APTO)

Aptose Biosciences Inc. (NASDAQ:APTO – Get Rating) (TSE:APS) – Equities research analysts at Oppenheimer upped their FY2025 earnings per share estimates for Aptose Biosciences in a research note issued on Monday, May 9th. Oppenheimer analyst M. Biegler now forecasts that the biotechnology company will post earnings per share of $0.29 for the year, up from their previous forecast of $0.27.

Aptose Biosciences (NASDAQ:APTO – Get Rating) (TSE:APS) last issued its earnings results on Monday, May 9th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.15) by $0.03. During the same quarter in the prior year, the business posted ($0.18) earnings per share.

APTO has been the topic of a number of other research reports. HC Wainwright reissued a “buy” rating on shares of Aptose Biosciences in a research note on Wednesday, March 23rd. StockNews.com began coverage on Aptose Biosciences in a research note on Thursday, March 31st. They issued a “sell” rating on the stock. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Aptose Biosciences in a research report on Friday, April 1st. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $7.50.

Shares of APTO stock opened at $1.07 on Wednesday. The firm’s 50 day moving average price is $1.21 and its two-hundred day moving average price is $1.51. Aptose Biosciences has a 52-week low of $1.00 and a 52-week high of $5.78. The stock has a market cap of $98.68 million, a PE ratio of -1.47 and a beta of 1.50.

Institutional investors have recently modified their holdings of the stock. UBS Group AG lifted its holdings in Aptose Biosciences by 102.1% during the third quarter. UBS Group AG now owns 18,478 shares of the biotechnology company’s stock worth $40,000 after acquiring an additional 9,333 shares in the last quarter. Jump Financial LLC lifted its holdings in shares of Aptose Biosciences by 11.3% during the 3rd quarter. Jump Financial LLC now owns 105,202 shares of the biotechnology company’s stock valued at $229,000 after purchasing an additional 10,702 shares in the last quarter. Squarepoint Ops LLC acquired a new position in shares of Aptose Biosciences in the 3rd quarter valued at approximately $34,000. Gleason Group Inc. acquired a new position in shares of Aptose Biosciences in the 1st quarter valued at approximately $25,000. Finally, Rockefeller Capital Management L.P. raised its holdings in Aptose Biosciences by 1,334.8% during the 4th quarter. Rockefeller Capital Management L.P. now owns 21,809 shares of the biotechnology company’s stock worth $29,000 after buying an additional 20,289 shares during the period. 34.21% of the stock is currently owned by institutional investors and hedge funds.

Aptose Biosciences Company Profile (Get Rating)

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.

Further Reading